Scan to Download
One power score. Smarter investment decisions
Apimeds Pharmaceuticals US Inc
APUS2.020USD
+0.190+10.38%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
USD0.000After-hours (ET)
25.40MMarket Cap
LossP/E TTM
Apimeds Pharmaceuticals US Inc
2.020
+0.190+10.38%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-1726.14%-3.36M
92.28%-20.31K
70.75%-99.62K
31.47%-186.75K
-3027.00%-184.06K
-2879.95%-263.10K
-1606.71%-340.57K
---272.50K
---5.89K
---8.83K
---19.95K
Net income from continuing operations
-492.44%-2.66M
-35.73%-402.40K
45.03%-311.63K
-202.24%-332.52K
-1145.60%-449.36K
-358.71%-296.47K
-660.07%-566.97K
---110.02K
---36.08K
---64.63K
---74.59K
Operating gains losses
--232.00
----
----
----
----
----
----
----
----
----
----
Other non-cash items
-4.13%13.06K
41.28%26.78K
390.27%24.85K
--22.53K
--13.62K
--18.95K
--5.07K
----
--0.00
--0.00
----
Change in working capital
-1171.09%-2.60M
5395.87%355.31K
0.38%213.73K
166.32%113.13K
48639.92%243.19K
--6.46K
9984.63%212.91K
---170.57K
---501.00
--0.00
---2.15K
-Change in prepaid expenses
-178866000.00%-1.79M
-96.82%40.00
-99.54%734.00
100.00%0.00
--1.00
--1.26K
21798.36%160.08K
---171.67K
--0.00
--0.00
--731.00
-Change in payables and accrued expense
-435.57%-816.06K
6506.72%344.01K
231.64%175.23K
10184.36%113.13K
48639.72%243.18K
--5.21K
1931.47%52.84K
--1.10K
---501.00
--0.00
---2.88K
Cash from non-recurring investing activities
Cash from operating activities
-1726.14%-3.36M
92.28%-20.31K
70.75%-99.62K
31.47%-186.75K
-3027.00%-184.06K
-2879.95%-263.10K
-1606.71%-340.57K
---272.50K
---5.89K
---8.83K
---19.95K
Investing cash flow
Net cash from continuing investing activities
--13.37K
----
----
----
----
----
----
----
----
----
----
Capital expenditures
--13.37K
----
----
----
----
----
----
----
----
----
----
Net cash flow from disposal of fixed assets
--13.37K
----
----
----
----
----
----
----
----
----
----
Cash from non-current investing activities
Net cash flow from investing activities
---13.37K
----
----
----
----
--0.00
--0.00
----
----
--0.00
----
Financing cash flow
Cash flow from continuous financing activities
11759.45%11.86M
--267.20K
--76.50K
-85.34%150.00K
--100.00K
-100.00%0.00
-100.00%0.00
--1.02M
--0.00
--9.00K
--282.90K
Net cash flow from debt Issuance/repayment
-100.00%0.00
--250.00K
--0.00
--150.00K
--100.00K
----
----
----
----
----
--260.00K
Net cash flow from common stock issuance/repurchase
--11.95M
----
----
----
----
----
--55.00K
--1.00M
----
----
----
Net cash flow from other financing activities
---93.60K
--17.20K
239.09%76.50K
-100.00%0.00
--0.00
-100.00%0.00
-340.17%-55.00K
--23.10K
--0.00
--9.00K
--22.90K
Net cash from non-recurrent financing activities
Net cash from financing activities
11759.45%11.86M
--267.20K
--76.50K
-85.34%150.00K
--100.00K
-100.00%0.00
-100.00%0.00
--1.02M
--0.00
--9.00K
--282.90K
Net cash flow
Beginning cash balance
69.86%250.34K
-99.16%3.46K
--26.57K
13787.28%63.33K
2223.89%147.38K
6551.77%410.48K
--0.00
--456.00
--6.34K
--6.17K
--0.00
Current period cash flow changes
10194.56%8.48M
193.84%246.89K
93.21%-23.12K
-104.90%-36.76K
-1328.05%-84.06K
-153959.65%-263.10K
-229.52%-340.57K
--750.60K
---5.89K
--171.00
--262.94K
Ending cash balance
13694.21%8.74M
69.86%250.34K
101.01%3.46K
-96.46%26.57K
13787.28%63.33K
2223.89%147.38K
-229.52%-340.57K
--751.05K
--456.00
--6.34K
--262.94K
Free cash flow
---3.37M
----
----
----
----
----
----
----
----
----
----
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
